Powered by

On October 28, biological drug and product manufacturer, Samsung BioLogics, successfully raised $2bn in what is the world’s largest healthcare sector IPO since Healthscope’s $2.1bn offering in 2014. The deal priced at the top of the range and is also South Korea’s largest IPO in 6 years.

As a trusted financial platform partner, Dealogic helped the bookrunners seamlessly execute the transaction through the DealManager network, who were also kept updated with real-time mobile access via Pulse.

Transaction Details

Issuer: Samsung BioLogics

Nationality: South Korea

Industry: Healthcare

Deal Value ($m): 1,969

Deal Type: IPO

Bookrunners: Korea Investment & Securities, Citi, NH Investment & Securities, JPMorgan, and Credit Suisse

Key Points

Top 3 global healthcare IPOs in 2016 YTD

  1. Samsung BioLogics, $2.0bn | South Korea | Oct 2016
  2. ConvaTec Group, $1.8bn | United Kingdom | Oct 2016
  3. China Resources Pharmaceutical Group, $1.8bn | Hong Kong | Oct 2016

Top 3 South Korean IPOs on record

  1. Samsung Life Insurance, $4.4bn | Insurance | Apr 2010
  2. Lotte Shopping, $3.7bn | Retail | Jan 2006
  3. Samsung BioLogics, $2.0bn | Healthcare | Oct 2016

 

For more information on why South Korea is Asia’s ECM bright spot, watch our video here.

 

 

More in ECM:

  1. Report

    Foreign issuers tap US capital markets for record amount

    April 2017

  2. Video

    Strong first quarter for US equity capital markets

    April 2017

  3. Report

    Key trends that shaped the markets in Q1 2017

    April 2017

  4. Video

    Resurgence in Asian equity capital market offerings

    March 2017